FDA clears Thermo Fisher multi-infection PCR test

By LabPulse.com staff writers

February 17, 2021 -- The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) to Thermo Fisher Scientific for the company's multi-infection TaqPath polymerase chain reaction (PCR) kit in differentiating the novel coronavirus from influenza.

Thermo Fisher's TaqPath COVID-19, Flu A, Flu B Combo Kit is a real-time PCR test for the detection and differentiation of RNA from the novel coronavirus and flu viruses that have been circulating. The test is effective for differentiating these infections, the company said.


Copyright © 2021 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?